In contrast to breast cancers, the survival data from the Human Protein Atlas and TCGA-COAD cohort showed that FOLR2 mainly indicated an unfavorable prognosis in colorectal cancer, implying its pro-tumor immunological function in colorectal tumors. This evidence concerns the gene FOLR2 and breast cancer.